PMID: 8584611Oct 1, 1995Paper

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

Psychopharmacology
P KarlssonF A Wiesel

Abstract

SCH 39166 is the first selective D1 dopamine receptor antagonist developed for the treatment of schizophrenic patients. To examine potential antipsychotic effect, tolerability and safety, SCH 39166 was given orally to 17 acutely ill drug free schizophrenic patients (DSMIIIR) in an open 4-week study. Doses were escalated from 10 to 100 mg b.i.d. according to a fixed schedule over 17 days and remained at 100 mg b.i.d. for another 11 days. The drug was withdrawn prematurely in ten patients because of deterioration or refusal to take SCH 39166. In the nine patients participating for more than 2 weeks, none had an apparent reduction of BPRS or CGI scores. Side effects were agitation, akathisia and emesis in single patients. After withdrawal of SCH 39166 of the patients improved when treated with classical neuroleptics or clozapine. The result of the study does not support the prediction that selective D1 dopamine receptor antagonism will produce antipsychotic effects in schizophrenia.

References

Aug 15, 1978·European Journal of Pharmacology·P E SetlerH L Saunders
Feb 11, 1992·Trends in Pharmacological Sciences·D R Sibley, F J Monsma
Sep 4, 1991·European Journal of Pharmacology·D McHugh, V Coffin
Dec 1, 1991·Journal of Neurochemistry·R D McQuadeA Barnett
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·C HärnrydB Gullberg
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1986·Advances in Experimental Medicine and Biology·G SedvallC Halldin
Mar 11, 1986·European Journal of Pharmacology·C F Saller, A I Salama
Oct 1, 1986·Archives of General Psychiatry·G SedvallF A Wiesel
May 1, 1966·Archives of General Psychiatry·M P Bishop, D M Gallant
Aug 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·W M BraudeS M Gore
Jan 1, 1984·Acta Psychiatrica Scandinavica. Supplementum·C HärnrydA Aberg-Wistedt
Jan 1, 1993·Schizophrenia Bulletin·J M Kane, S R Marder
Jan 1, 1963·Acta Pharmacologica Et Toxicologica·A CARLSSON, M LINDQVIST

❮ Previous
Next ❯

Citations

Jan 1, 1996·Journal of Neural Transmission·R MarksteinD Hoyer
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Oct 1, 1995·Psychopharmacology·T R Barnes, J Gerlach
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Shitij KapurMing Li
Aug 19, 2003·European Journal of Pharmacology·John L NeumeyerRoss J Baldessarini
Mar 28, 1998·Neuropharmacology·U D'SouzaP R Buckland
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·R D SpealmanT V Khroyan
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Jun 3, 2009·Schizophrenia Bulletin·Paul D Morrison, R M Murray
Dec 5, 2000·Behavioural Pharmacology·B Scatton, D J Sanger
Sep 16, 1995·Lancet·G Sedvall, L Farde
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lena ScottAnita Aperia
Dec 9, 2004·Expert Opinion on Therapeutic Targets·David J Sanger
Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller
Jan 1, 2002·Expert Review of Neurotherapeutics·Hugh M Jones, Lyn S Pilowsky
Oct 11, 2007·The International Journal of Neuropsychopharmacology·Maria A StasiPaolo Carminati
May 29, 2016·Progress in Neurobiology·S ButiniH Stark
Sep 4, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lukasz BojarskiUrszula Wojda
Mar 31, 2017·International Journal of Molecular Sciences·Matea Nikolac PerkovicNela Pivac
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Dec 20, 2003·Annals of the New York Academy of Sciences·Marc LaruelleAnissa Abi-Dargham
Jun 24, 2018·Synapse·Yong Kee Choi, Frank I Tarazi
Mar 1, 2003·Molecular Psychiatry·B Le FollP Sokoloff
Feb 10, 2006·Expert Review of Neurotherapeutics·James M Stone, Lyn S Pilowsky
Jun 24, 2015·British Journal of Pharmacology·Laura J MosherMarco Bortolato
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here